Glaxo Smith Kline's antibody treatment works against Omicron

 

Research by GlaxoSmithKline shows its Covid-19 antibody treatment is effective against the full combination of mutations in the new Omicron variant, reported Deirdre Hipwell (7 December 2021). Tests done in-vitro against a pseudo-virus that recreates a synthesised version of Omicron showed that sotrovimab, Glaxo’s antibody treatment, stands up to all mutations in the spike protein of the Omicron variant and not just the key mutations. The tests included all 37 mutations identified to date in the spike protein.

Other news